CP 654743
Latest Information Update: 23 Jul 2002
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antibacterials; Ketolides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory tract infections
Most Recent Events
- 26 Sep 2000 New profile
- 26 Sep 2000 Preclinical development for Respiratory tract infections in USA (Unknown route)